Glioblastoma del adultoFase 1NCT04573140Artículos
ARNm tumoral total autólogo
Vacunas de partículas lipídicas de ARN (ARN-LP) para gliomas pediátricos de alto grado (GAGp) y glioblastoma (GBM) del adulto recién diagnosticados
Células CAR T GD2 en gliomas pontinos intrínsecos difusos (GPID) y glioma difuso de línea media (GDLM) espinal
Lo que dice el vídeo
In the middle of the brain stem there is a bulge called the pons. Everything that keeps you alive without your attention runs through it. Breathing, heart rate, the nerves for swallowing and speaking and moving your eyes.
Diffuse intrinsic pontine glioma grows there. About three hundred children in the United States are diagnosed each year, most of them between five and ten years old. The tumor does not sit in a lump. It grows woven through the pons, so it cannot be taken out, because there is nothing to take out without taking the child's breathing with it. Radiation helps for a while. Half of these children live about eleven months, and fewer than one in a hundred are alive five years later. It is the leading cause of brain cancer death in children.
For decades, nothing added to radiation changed that.
Then a lab at Stanford went looking for a handle. Nearly eight in ten of these tumors carry one tiny change. In histone H three, the spool that DNA winds around, a single amino acid is swapped. That one swap scrambles the instructions that tell a cell which genes to read. And it appears to switch on the enzymes that build a molecule called G D two, a sugar and fat structure that sits on the outside of the cell.
Every tumor sample they tested was covered in it. Healthy brain was not. They had found a flag.
So how do you attack a flag on a cell inside a brain stem? Not with a drug. With a cell.
Take the patient's own T cells, the immune system's hunters. In the lab, give them a new receptor: an outer piece that grips G D two, wired to the machinery that tells a T cell to kill. That is a C A R T cell, a living drug. It takes about a week to make.
The first infusion goes into a vein. Later doses go somewhere unusual, straight into the fluid that bathes the brain, through a small port under the scalp. That port matters twice over, because when the T cells reach the tumor and start working, the swelling arrives in the tightest possible place. The team named the problem and built a routine for it. Watch the pressure, drain fluid through the same port, treat the swelling. So far, in every patient, it has reversed.
Thirteen children and young adults enrolled in the first part of the trial, and eleven were treated. Nine of the eleven improved, in how they felt, on their scans, or both. Four tumors shrank by half or more, and one disappeared. That young man is now more than four years past his diagnosis and still getting infusions. A five-year-old regained the use of her hand and grew two inches. Most of the others, in time, got worse.
Cautious optimism is the phrase the researchers use, and they mean both words. They have since found part of the reason the effect fades. Patients' immune systems learn to attack the engineered receptor itself.
The trial is still open at Stanford, now for ages two to sixty, testing versions designed to last longer. It is led by Michelle Monje. The questions are still safety and dose.
Everything in this film comes from the published record, and it is not medical advice.
Fuentes de este vídeo
The pons runs breathing, heart rate, and the nerves for swallowing, speaking and eye movement; About three hundred US children a year, most between five and ten; Grows woven through the pons and cannot be removed; Radiation helps for a while
About three hundred US children a year, most between five and ten; For decades nothing added to radiation changed that; Nearly eight in ten carry one amino-acid swap in histone H3; Swelling in the tightest possible place; the team named it and built a routine; it has reversed in every patient (+1 more lines)
Radiation helps for a while
Monje M. Nature, 2025
Half live about eleven months; fewer than one in a hundred alive after five years; Leading cause of brain cancer death in children; A CAR T cell: the patient's own T cells given a receptor that grips GD2, wired to the kill machinery; About a week to make (+6 more lines)
Mount CW. Nat Med, 2018
The swap appears to switch on the enzymes that build GD2; GD2 is a sugar-and-fat molecule on the cell surface; every tumor sample was covered in it, healthy brain was not
Majzner RG. Nature, 2022
A CAR T cell: the patient's own T cells given a receptor that grips GD2, wired to the kill machinery; Swelling in the tightest possible place; the team named it and built a routine; it has reversed in every patient; A five-year-old regained the use of her hand and grew two inches
Chen Y. medRxiv, 2026
That young man is more than four years past diagnosis and still getting infusions; Patients' immune systems learn to attack the engineered receptor
El fármaco
Células T autólogas transducidas con un vector retroviral (14g2a-CD8.BB.z.iCasp9) que expresan un receptor de antígeno quimérico anti-GD2
Fludarabina 30 mg/m2 al día IV los días -4, -3 y -2
Objetivos principales: * Determinar la viabilidad de fabricar células T autólogas transducidas con el vector retroviral 14g2a-CD8-BBz-iCasp9 que expresan un receptor de antígeno quimérico anti-GD2 (GD2CART) para su administración a participantes con glioma difuso de línea media (GDLM) con mutación H3K27M, usando un vector retroviral y dasatinib en el sistema CliniMACS Prodigy® de Miltenyi. * Evaluar la seguridad e identificar la dosis máxima tolerada (DMT) y/o la dosis recomendada para fase 2 (DRF2), la vía y el esquema de GD2CART y de la quimioterapia linfodepletora en participantes con GDLM con mutación H3K27M. * Evaluar la seguridad de la DMT/DRF2, la vía y el esquema de GD2CART en cohortes de expansión de participantes con GDLM con mutación H3K27M.
El estudio
El objetivo principal de este estudio es comprobar si las células CAR T dirigidas contra GD2 (GD2CART) pueden fabricarse con éxito y administrarse de forma segura a niños y adultos con glioma difuso de línea media (GDLM) con mutación H3K27M. Los participantes elegibles pueden tener un GDLM originado en la protuberancia (llamado glioma pontino intrínseco difuso, GPID), en la médula espinal o en otras zonas del cerebro, como el tálamo
Requisitos
Criterios de inclusión tal como figuran en el registro, recortados. La lista completa, con las exclusiones, está en el registro actualizado.
Para ti, o para alguien a quien quieres
Un diagnóstico complejo trae preguntas nuevas cada semana, dentro de un ensayo y fuera de él. Triangle reúne todo tu expediente médico, lo lee contigo en lenguaje claro y te ayuda, a ti y a tu familia, a decidir qué preguntar después.
Después, $9 al mes. Cancela cuando quieras.
Solicitados a tus hospitales y clínicas a través de las redes nacionales. Añade estudios de imagen, patología y cualquier documento en papel.
Informes explicados a medida que llegan, con valores de laboratorio que puedes seguir antes del tratamiento, durante un ensayo y después.
Pregunta sobre tu propio expediente y llega con preguntas para tu oncólogo o el equipo del ensayo.
Comparte un mismo perfil con la familia que te ayuda y con tus médicos.
Los miembros también reciben un análisis profundo de sus historiales y de cualquier dato de secuenciación, incluidos los ensayos clínicos que podrían encajar, revisado por un médico colegiado antes de recibirlo.
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.